Literature DB >> 430477

Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.

R A Conrad, G J Cullinan, K Gerzon, G A Poore.   

Abstract

While structure-activity relationships for vinblastine (VLB), vincristine, deacetyl-VLB, and deacetyl-VLB amide (vindesine, VDS) in several tumor and leukemia models have been reported previously, the present study explores these relationships for a series of N-substituted vindesine analogues. These compounds were prepared from the reaction of deacetyl-VLB acid azide with the appropriate amines and were characterized by mass spectral analysis, 1H and 13C NMR spectra, electrometric titration, and infrared spectra. N-Alkylvindesines have reduced activity compared to that of VDS against the Gardner lymphosarcoma (GLS). N-beta-Hydroxyethyl-VDS surpasses vindesine in its activity against the Ridgway osteogenic sarcoma and the GLS, whereas against the B16 melanoma it is less active than VDS. N-beta-(4-Hydroxyphenethyl)-VDS, envisaged as a substrate for the enzyme tryosinase, was shown to be more active than VDS against the B16 melanoma but has only marginal activity against the GLS. In terms of collective antitumor activity against the model systems used, vindesine emerges as the congener with optimum qualities. Bis(N-ethylidenevindesine) disulfide, the first example of a bridged bisvindesine and comparable to VDS in its antitumor profile, shows evidence of activity against a P388/VCR leukemia strain known to be resistant to maytansine as well as to vincristine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 430477     DOI: 10.1021/jm00190a008

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Fluorescent vinblastine probes for live cell imaging.

Authors:  Labros G Meimetis; Randy J Giedt; Hannes Mikula; Jonathan C Carlson; Rainer H Kohler; David B Pirovich; Ralph Weissleder
Journal:  Chem Commun (Camb)       Date:  2016-08-02       Impact factor: 6.222

2.  In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates.

Authors:  D A Johnson; J L Zimmermann; B C Laguzza; J N Eble
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Antitumor properties of vindesine-monoclonal antibody conjugates.

Authors:  G F Rowland; C A Axton; R W Baldwin; J P Brown; J R Corvalan; M J Embleton; V A Gore; I Hellström; K E Hellström; E Jacobs
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling.

Authors:  M M Cornwell; A R Safa; R L Felsted; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

5.  A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.

Authors:  J R Johnson; C H Ford; C E Newman; C S Woodhouse; G F Rowland; R G Simmonds
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640

6.  Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.

Authors:  C H Ford; C E Newman; J R Johnson; C S Woodhouse; T A Reeder; G F Rowland; R G Simmonds
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.